Enzo Biochem Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
Retrieved on:
Tuesday, October 12, 2021
Company, IHC, Efficiency, PPP, Pharmacy, Incidence, Risk, Proxy, Ursula Horsman Memorial Hospital, CLX, Conference, ELS, COVID-19, NEW, EBITDA, COVID-19 testing, Drug development, EUA, Collection, Laboratory, Marketing, Growth, FY, Industry, Cancer, Investment, School, Research, Board, FDA, MD, GAAP, EPS, Review, Immunohistochemistry, ENZ, Conference call, Update, RNA, Antigen, Total, Director, Severe acute respiratory syndrome coronavirus 2, Yoy, Awareness, NYSE, Infection, GLOBE, SG, Eye, PCR, Patient, Public expenditure, Travel, Internet, Sample Collection for Investigation of Mars, Lithium, Fossil fuel, Medical device, Pharmaceutical industry, Vaccine, Video game, Animal
NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported operating results for the fiscal year and fourth quarter ended July 31, 2021 and provided a business update on recent corporate and operational developments.
Key Points:
- In November 2020, Enzo announced the appointment of Ian B. Walters, MD, and Mary Tagliaferri, MD, to the Board of Directors.
- Enzo Life Sciences (ELS) fiscal 2021 revenues amounted to $30.7 million, up 16% from fiscal 2020.
- Total fourth quarter revenues were $24.8 million, an increase of 27% from $19.5 million in the fourth quarter last year, but a decrease of 24% sequentially.
- Enzo Clinical Lab revenue increased 30% to $16.8 million from $12.9 million in the fourth quarter 2020.